Omeros (OMER) Insider Arnold Hanish Buys 15,000 Shares
Arnold Hanish purchased 15,000 shares of Omeros Corporation on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Arnold Hanish bought 15,000 shares of Omeros Corporation ($OMER) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OMER is up 4.3% after 1 week, down 6.3% after 1 month and up 57.6% to date (from the $10.28 close on Jun 18, 2026).
OMER
Omeros Corporation
Key Points
- Arnold Hanish bought 15,000 shares of Omeros Corporation at a price of $10.33 each on June 18, 2026.
- Multiple insiders, including Thomas Cable and Peter Demopulos, also purchased 15,000 shares each on the same day.
- Analysts have a positive outlook, with HC Wainwright maintaining a 'Buy' rating and a price target of $33.
Get $OMER trade alerts by text
We text you when insiders, Congress or big funds trade $OMER. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Omeros Corporation alert may contain errors. Disclosures
Insider Buying and Selling at Omeros Corporation
Arnold Hanish bought 15,000 shares of Omeros Corporation (NasdaqGM: OMER) at $10.33 each on June 18, 2026. This trade reflects a significant insider commitment, as multiple executives made similar purchases on the same day. Hanish's buy adds to the growing confidence among insiders in the company's future prospects.
A Surge in Insider Buying
On June 18, 2026, several insiders at Omeros Corporation made substantial purchases, each acquiring 15,000 shares. Thomas Cable, Peter Demopulos, Thomas Bumol, Rajiv Shah, Diana Perkinson, and Leroy Hood all participated in this insider buying spree. Each transaction involved an acquisition of shares at the market price, signaling a strong belief in the company's direction.
Analysts Set New Price Targets
Analysts are generally optimistic about Omeros Corporation's future. On June 26, 2026, HC Wainwright & Co. maintained a 'Buy' rating with a price target of $33, though it was downgraded from a previous target of $40. Cantor Fitzgerald also upgraded its rating to 'Overweight' on September 22, 2026, with a price target of $22. This analyst support comes as Omeros continues to develop its promising biopharmaceutical products.
How Omeros Corporation Stock Has Traded
Omeros stock was trading at $10.33 on June 18, 2026, well below its 52-week high of $21.24. The shares have seen fluctuations, dropping from a previous close of $18.43. This recent insider activity occurs during a time when the stock is trading significantly lower than its highs, potentially creating an opportunity for growth.
What Omeros Corporation Does
Omeros Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington. It focuses on developing treatments for immunologic diseases and has several products in various stages of clinical trials. The recent insider purchases may reflect confidence in the company's ongoing projects and potential market impact.
What's Ahead for Omeros Corporation
Investors will be watching Omeros closely, especially with the next earnings report set for November 12, 2026. As always, the recent insider trades provide a backward-looking view of their positions and may not represent current holdings. Further updates will be crucial for understanding the company's trajectory and insider sentiment.
Related Filing Alerts
Source: Arnold Hanish's Form 4 filing on $OMER (Jun 18, 2026). Find the original filing: OMER Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts